VJOncology is committed to improving our service to you

ESMO 2018 | Dabrafenib/trametinib/pembrolizumab for advanced melanoma: update from KEYNOTE-022

VJOncology is committed to improving our service to you

Paolo Ascierto

Pembrolizumab is making waves in multiple cancer types, and melanoma is no exception. Here, Paolo Ascierto, MD, of the National Cancer Institute of Naples, Naples, Italy, gives us an update on the KEYNOTE-022 trial of dabrafenib and trametinib plus pembrolizumab for BRAF-mutated advanced melanoma (NCT02130466). Dr Ascierto highlights the interesting progression-free survival results and ambitious trial design. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter